Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9593MR)

This product GTTS-WQ9593MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9593MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2362MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ5655MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ7102MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ1074MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ2079MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ2964MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ11915MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ10808MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW